CAD & Atherosclerosis
From the Journals
Study questions need for repeat Lp(a) testing
A large cohort study finds that a baseline test for lipoprotein(a) can help determine cardiovascular disease risk and that repeat testing isn't...
Feature
Novel drug targets raised Lp(a): topline results released
Significant reductions in lipoprotein(a) were sustained out to 150 days in patients without cardiovascular disease in top-line phase 1 results...
From the Journals
Merits of short DAPT, de-escalation in ACS challenge guidelines
Results from the meta-analysis should put the alternative strategies on par with each other or even dethrone standard DAPT in current guidelines,...
Conference Coverage
Chronic marijuana use linked to recurrent stroke
“It’s essential to raise awareness among young adults about the impact of chronic habitual use of marijuana, especially if they have established...
From the Journals
Anxiety in men tied to risk factors for CVD, diabetes
Worry and neuroticism, both aspects of anxiety, when seen in midlife are associated with differences in risk for heart disease and diabetes that...
Latest News
AHA annual stats update highlights heart-brain connection
“The global rate of brain disease is quickly outpacing heart disease.”
From the Journals
VARC-3 TAVR technical failure definition ‘highly clinically relevant’
The new endpoint was met in the majority of patients, but observers say there’s still a need for further improvements in TAVR devices, techniques...
Feature
Dr. Jeremiah Stamler, pioneer of preventive cardiology, dies at 102
The internationally renowned physician’s research altered the way the world views diet and heart health, and influenced public health policy for...
From the Journals
Vitamin D shows no survival benefit in nondeficient elderly
“This is not dissimilar to research with many other nutrients showing that increasing intake above the adequate intake has no further health...
From the Journals
Ischemic stroke rates higher in young women than young men
Young women may be at a higher risk of ischemic stroke than young men, representing a “significant departure from our current scientific...
Feature
Uptake uncertain for potent new LDL-lowerer inclisiran
Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its U.S. debut in early 2022 with cautious uptake prospects.